Trials / Completed
CompletedNCT01526434
Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol
An Open-label, Observational 12-week Study to Assess Health-related Quality of Life and Patient-reported Outcomes in Patients With Rheumatoid Arthritis Treated With Certolizumab Pegol
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 81 (actual)
- Sponsor
- UCB Pharma SA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective is to assess Health-Related Quality of Life (HRQoL) according to physical function, as measured by a specific Questionnaire (Health Assessment Questionnaire), in Rheumatoid Arthritis (RA) patients who begin therapy with subcutaneous Anti-Tumour Necrosis Factor alpha (TNFα) Certolizumab Pegol (CZP).
Detailed description
An open-label, prospective, and post-authorization observational study. This non-interventional study is designed to establish the importance of the measurement of HRQoL data and patient-reported outcomes in clinical practice in patients with RA, and to assess efficacy and safety use of CZP according to the summary of product characteristics.
Conditions
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2012-02-03
- Last updated
- 2014-03-19
Locations
15 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01526434. Inclusion in this directory is not an endorsement.